Target intelligence / Profile preview

DNA topoisomerase 2-alpha (TOP2A)

Target
TOP2A
Molecular classification
Enzyme, Type IIA DNA topoisomerase
01

Overview

DNA topoisomerase 2-alpha (TOP2A) is an essential eukaryotic type IIA topoisomerase that functions as a homodimer to alter DNA topology by creating transient, ATP‑dependent double‑strand breaks and passing a second DNA segment through the break; it is crucial for decatenation of sister chromatids, chromosome condensation, and faithful chromosome segregation in proliferating cells. Human Top2α is the primary isoform targeted by frontline anticancer agents that form ternary drug–enzyme–DNA cleavage complexes; structural and cryo‑EM studies reveal the “two‑gate” mechanism, active‑site residues (including catalytic Tyr805 in human Top2α), and allosteric coupling between the ATPase and DNA‑cleavage cores that underlie drug action and opportunities for isoform‑selective inhibition.

Other names
Topoisomerase II alphaTop2αDNA topoisomerase II alphahTopo IIα
02

Mechanism of action

Topoisomerase II poison: drugs such as doxorubicin and etoposide stabilize the Top2α–DNA cleavage complex, producing persistent double‑strand breaks that trigger cell death in dividing cells

03

Biological functions

DNA topology regulation (removal of supercoils and tangles)Chromosome condensation and structureDecatenation of replicated chromosomes and chromosome segregation during mitosisRoles in transcriptional processes
04

Disease associations

Cancer (TOP2A is essential for proliferating cells and is a major chemotherapy target; overexpression/amplification is observed in several cancers)
05

Safety considerations

Therapy with Top2 poisons is associated with secondary malignancies (therapy‑related leukemias) due to off‑target Top2 poisoning, including effects on the Top2β isoform
06

Interacting drugs

Doxorubicin (anthracycline)

2 more in the full profile.

07

Biomarkers

TOP2A expression or copy number status (amplification/overexpression) as a prognostic or predictive marker in certain cancers, including ovarian cancer in some studies

Beyond the preview

Go deeper on DNA topoisomerase 2-alpha (TOP2A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNA topoisomerase 2-alpha (TOP2A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call